Fig. 5From: Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLProteomic signatures selected to predict ex vivo response to quizartinib using the A LASSO, B Elastic Net, and C logistic regression cluster quizartinib resistant cells from parentals. D The same signature from (C) but with additional cell lines that were developed as models of late and early resistanceBack to article page